UNSPSC 51144201: Aminorex

This classification denotes an anorexiant with the molecular formula C9H10N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 2SH16612I9, chemically known as 4,5-dihydro-5-phenyl-2-oxazolamine but more generally known as aminorex, which bears US NIH Compound Identifier 16630. Aminorex most often comes in base and fumarate forms. European Medicines Agency schedules Aminorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05448MIG. The term AMINOREX is an International Non-Proprietary Name.

UNSPSC 51144201 Aminorex is a Commodity code that captures pharmaceutical supply procurement by state and local health agencies, though recent opportunities show the code tagged to a broader range of health-related pharmaceutical and drug-management products than the code name alone suggests. State and local governments buying under this code are acquiring naloxone and drug deactivation systems for community health initiatives, generic pharmaceuticals and over-the-counter products for multi-state cooperative purchasing networks, and exploring direct-to-manufacturer prescription fulfillment models to optimize pharmacy benefit management. The issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances administering shared pharmaceutical contracts across member jurisdictions. Procurement occurs through traditional competitive bidding (IFB), requests for proposals (RFP), and exploratory requests for information (RFI) to gather vendor capabilities before formal solicitation.

Recent activity spans Florida, Texas, Minnesota, and Oregon through a mix of single-jurisdiction and multi-state cooperative vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023, on a fixed-fee basis with a two-year initial term and one-year renewal option. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026; evaluation weights 75 percent on price competitiveness, with vendors required to maintain relationships with at least two of three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to solicit vendor information about implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking vendor experience with direct contracting models outside traditional pharmacy benefit manager and wholesaler channels.